Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: A review of the literature

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4140-4149

  Francissen, Claire M T P ^a   Dings, Pim J M ^a   Van Dalen, Thijs ^b   Strobbe, Luc J A ^c   Van Laarhoven, Hanneke W M ^a   De Wilt, Johannes H W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MEDLINE; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SYSTEMATIC REVIEW;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REVIEW LITERATURE AS TOPIC; SENTINEL LYMPH NODE BIOPSY;

EID: 84876458588     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2490-4     Document Type: Review

References (68)

1. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-98.
2. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983-90. (Pubitemid 44804136)
3. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-20. (Pubitemid 46291835)
4. Straver ME, Meijnen P, Van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol. 2010;28:731-7.
5. Hurkmans CW, Borger JH, Rutgers EJ. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol. 2003;68:233-40. (Pubitemid 38373423)
6. Straver ME, Meijnen P, Van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854-61.
7. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the Sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34:508-13. (Pubitemid 351514885)
8. Yeoh EK, Denham JW, Davies SA, et al. Primary breast cancer: complications of axillary management. Acta Radiol Oncol. 1986;25:105-108. (Pubitemid 16061671)
9. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426-32.
10. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946-53.
11. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462-8.
12. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567-75.
13. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657-63. (Pubitemid 47372604)
14. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138:52-6. (Pubitemid 36055648)
15. Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34-40. (Pubitemid 40486639)
16. Hwang RF, Gonzalez-Angulo A, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723-30. (Pubitemid 47257646)
17. Van Der Vegt B, Doting MH, Jager PH, et al. Axillary recurrence after sentinel lymph node biopsy. Eur J Surg Oncol. 2004, 30: 715-20. (Pubitemid 39107060)
18. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS ? RT). Int J Radiat Oncol Biol Phys. 2006;66:1320-7.
19. Takei H, Kurosumi M, Yoshida T, et al. Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies. Breast Cancer. 2010;17:9-16.
20. Langer I, Guller U, Viehl CT, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol. 2009;16:3366-74.
21. Park J, Fey JV, Naik AM, et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462-8. (Pubitemid 46673143)
22. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17:S343-51.
23. Cyr A, Gillanders WE, Aft RL, et al. Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden. Ann Surg Oncol. 2010;17:S303-11.
24. Yegiyants S, Romero LM, Haigh PI, et al. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Arch Surg. 2010;145:564-9.
25. Meretoja TJ, Vironen JH, Heikkilä PS, et al. Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol. 2010;102:215-9.
26. Degnim AC, Zakaria S, Bouhey JC, et al. Axillary recurrence in breast cancer patients with isolated tumor cells in the sentinel lymph node [AJCC N0(i?)]. Ann Surg Oncol. 2010;17:2685-9.
27. Pugliese MS, Karam AK, Hsu M, et al. Predictors of completion axillary lymph node dissection in patients with immunohisto-chemical metastases to the sentinel lymph node in breast cancer. Ann Surg Oncol. 2010;17:1063-68.
28. Pernas S, Gil M, Benítez A, et al. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence. Ann Surg Oncol. 2010;17:772-7.
29. Zakaria S, Pantvaidya G, Reynolds CA, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different? Surgery. 2008;143:641-7.
30. Cox CE, Kiluk JV, Riker AI, et al. Significance of sentinel lymph node micrometastase in human breast cancer. J Am Coll Surg. 2008;206:261-8.
31. Schulze T, Mucke J, Markwardt J, et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol. 2006;93:109-19. (Pubitemid 43235256)
32. Haid A, Knauer M, Köberle-Wührer R, et al. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol. 2006;32:1180-5. (Pubitemid 44793674)
33. Swenson KK, Mahipal A, Nissen MJ, et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer. 2005;104:1834-9. (Pubitemid 41513165)
34. Schrenk P, Konstantiniuk P, Wölfl S, et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometa-static sentinel node. Br J Surg. 2005;92:707-13. (Pubitemid 40863189)
35. Fan YG, Tan YY, Wu CT, et al. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Ann Surg Oncol. 2005;12:705-11.
36. Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohisto-chemistry. Cancer. 2005;103:1581-6. (Pubitemid 40490018)
37. Carlo JT, Grant MD, Knox SM, et al. Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer. Proc (Bayl Univ Med Cent). 2005;18:103-7.
38. Fournier K, Schiller A, Perry RR, et al. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg. 2004;239:859-63.
39. Ganaraj A, Kuhn JA, Jones RC. Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node. Proc (Bayl Univ Med Cent). 2003;16:3-6.
40. Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126-30. (Pubitemid 40485931)
41. Liang WC, Sickle-Santanello BJ, Nims TA. Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am J Surg. 2001;182:365-8. (Pubitemid 33079088)
42. Calhoun KE, Hansen NM, Turner RR, et al. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg. 2005;190:588-91. (Pubitemid 41306082)
43. Geertsema D, Gobardhan PD, Madsen EVE, et al. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy. Ann Surg Oncol. 2010;17:2690-5.
44. Rutgers EJT. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol. 2008;26: 698-702. (Pubitemid 351264381)
45. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACO-SOG Z0011 trial. Semin Surg Oncol. 2001;20:230-7. (Pubitemid 32830834)
46. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol. 2000;55:263-72. (Pubitemid 30408372)
47. Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245-52. (Pubitemid 39331448)
48. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140-51. (Pubitemid 40486808)
49. Van la Parra RF, Ernst MF, Bevilacqua JL, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16:1128-35.
50. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institute Curie. Lancet. 1992;339:1245-8.
51. De Boer M, Van Deurzen CH, Van Dijck JA, et al. Micrometas-tases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653-63.
52. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma. Multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150-60. (Pubitemid 37099899)
53. Kuerer HM, Newman LA, Budzar AU, et al. Pathologic tumor response in breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998;4:230-6.
54. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92:14-23. (Pubitemid 40144188)
55. Vlastos G, Mirza NQ, Lenert JT, et al. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000;88:1417-24. (Pubitemid 30155180)
56. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72-78. (Pubitemid 30190367)
57. Chung MA, DiPetrillo T, Hernandez S, et al. Treatment of the axilla by tangential breast radiotherapy in women with invasive breast cancer. Am J Surg. 2002;184:401-2. (Pubitemid 35335944)
58. Rabinovitch R, Ballonoff A, Newman F, Finlayson C. Evaluation of breast sentinel lymph node coverage by standard radiation therapy fields. Int J Radiat Oncol Biol Phys. 2008;70:1468-71. (Pubitemid 351417768)
59. Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;3:383-8. (Pubitemid 40458313)
60. Van Wely BJ, Teerenstra S, Schinagl DA, et al. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg. 2011;98:326-33.
61. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688-97. (Pubitemid 32230869)
62. Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer. 1977;39:2827-39. (Pubitemid 8130398)
63. Whelan TJ, Olivotto I, Ackerman I, et al. NCIG-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. Paper presented at: ASCO annual meeting, 2011.
64. Jakub JW, Bryant K, Huebner M, et al. The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes. Ann Surg Oncol. 2011;18:86-93.
65. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
66. Morrow M, Giuliano AE. To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol. 2011; 18: 2413-5.
67. Cody HS 3rd, Houssami N. Axillary management in breast cancer: what's new for 2012? Breast. 2012;21(3):411-5.
68. Cody HS 3rd. SLN biopsy for large and/or multicentric breast cancers: should we worry? Eur J Surg Oncol. 2011;37:386-7.